



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

SOTORASIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SOTORASIB	LUMAKRAS	47400		GPI-10 (2153248000)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
 - The patient is 18 years of age or older
 - The patient has a KRAS G12C-mutation, as determined by an FDA-approved test
 - The patient has received at least one prior systemic therapy

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **120mg: #8 per day.**
- **320mg: #3 per day.**

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SOTORASIB (Lumakras)** requires the following rule(s) be met for approval:

- A. You have locally advanced or metastatic non-small cell lung cancer (NSCLC) (type of lung cancer that has grown outside the organ it started in but has not spread to other parts of the body or lung cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. You have a KRAS G12C-mutation (type of gene mutation), as determined by a Food and Drug Administration (FDA)-approved test
- D. You have received at least one prior systemic therapy (treatment that spreads throughout the body through the bloodstream)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

SOTORASIB

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lumakras.

REFERENCES

- Lumakras [Prescribing Information]. Thousand Oaks, CA: Amgen, Inc.; January 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/17/23

Created: 07/21

Client Approval: 03/23

P&T Approval: 07/21